Substituted 4H-3,1-benzoxazine-4-one Derivatives as Inhibitors of Cathepsin G

IF 1.9 4区 医学 Q3 CHEMISTRY, MEDICINAL Medicinal Chemistry Pub Date : 2024-04-27 DOI:10.2174/0115734064300678240408084822
Kholoud F. Aliter, Rami A. Al-Horani
{"title":"Substituted 4H-3,1-benzoxazine-4-one Derivatives as Inhibitors of Cathepsin G","authors":"Kholoud F. Aliter, Rami A. Al-Horani","doi":"10.2174/0115734064300678240408084822","DOIUrl":null,"url":null,"abstract":"Background: Cathepsin G (CatG) is a cationic serine protease with a wide substrate specificity. CatG has been reported to play a role in several pathologies, including rheumatoid arthritis, ischemic reperfusion injury, acute respiratory distress syndrome, and cystic fibrosis, among others. Objective: We aim to develop a new class of CatG inhibitors and evaluate their potency and selectivity against a series of serine proteases. Methods: We exploited chemical synthesis as well as chromogenic substrate hydrolysis assays to construct and evaluate the new inhibitors. Results: In this communication, we report on a new class of CatG inhibitors of 4H-3,1-benzoxazin- 4-one derivatives. We constructed a small library of seven substituted 4H-3,1-benzoxazin-4-one derivatives and identified their inhibition potential against CatG. Five molecules were identified as CatG inhibitors with values of 0.84-5.5 μM. Inhibitor 2 was the most potent, with an IC50 of 0.84 ± 0.11 μM and significant selectivity over representative serine proteases of thrombin, factor XIa, factor XIIIa, and kallikrein. Conclusion: Thus, we propose this inhibitor as a lead molecule to guide subsequent efforts to develop clinically relevant potent and selective CatG inhibitors for use as anti-inflammatory agents.","PeriodicalId":18382,"journal":{"name":"Medicinal Chemistry","volume":"44 1","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115734064300678240408084822","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Cathepsin G (CatG) is a cationic serine protease with a wide substrate specificity. CatG has been reported to play a role in several pathologies, including rheumatoid arthritis, ischemic reperfusion injury, acute respiratory distress syndrome, and cystic fibrosis, among others. Objective: We aim to develop a new class of CatG inhibitors and evaluate their potency and selectivity against a series of serine proteases. Methods: We exploited chemical synthesis as well as chromogenic substrate hydrolysis assays to construct and evaluate the new inhibitors. Results: In this communication, we report on a new class of CatG inhibitors of 4H-3,1-benzoxazin- 4-one derivatives. We constructed a small library of seven substituted 4H-3,1-benzoxazin-4-one derivatives and identified their inhibition potential against CatG. Five molecules were identified as CatG inhibitors with values of 0.84-5.5 μM. Inhibitor 2 was the most potent, with an IC50 of 0.84 ± 0.11 μM and significant selectivity over representative serine proteases of thrombin, factor XIa, factor XIIIa, and kallikrein. Conclusion: Thus, we propose this inhibitor as a lead molecule to guide subsequent efforts to develop clinically relevant potent and selective CatG inhibitors for use as anti-inflammatory agents.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
取代的 4H-3,1-苯并恶嗪-4-酮衍生物作为凝血酶 G 的抑制剂
背景:Cathepsin G(CatG)是一种阳离子丝氨酸蛋白酶,具有广泛的底物特异性。据报道,CatG 在多种病症中发挥作用,包括类风湿性关节炎、缺血再灌注损伤、急性呼吸窘迫综合征和囊性纤维化等。我们的目标是我们旨在开发一类新的 CatG 抑制剂,并评估它们对一系列丝氨酸蛋白酶的效力和选择性。研究方法我们利用化学合成和显色底物水解试验来构建和评估新的抑制剂。结果:在这篇通讯中,我们报告了一类新的 4H-3,1-苯并恶嗪-4-酮衍生物 CatG 抑制剂。我们构建了一个由 7 种取代的 4H-3,1-苯并恶嗪-4-酮衍生物组成的小型文库,并鉴定了它们对 CatG 的抑制潜力。其中五个分子被鉴定为 CatG 抑制剂,其抑制值为 0.84-5.5 μM。其中,抑制剂 2 的作用最强,其 IC50 值为 0.84 ± 0.11 μM,对凝血酶、XIa 因子、XIIIa 因子和 Kallikrein 等代表性丝氨酸蛋白酶具有显著的选择性。结论:因此,我们建议将这种抑制剂作为先导分子,以指导后续开发临床相关的强效、选择性 CatG 抑制剂作为抗炎药物的工作。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Medicinal Chemistry
Medicinal Chemistry 医学-医药化学
CiteScore
4.30
自引率
4.30%
发文量
109
审稿时长
12 months
期刊介绍: Aims & Scope Medicinal Chemistry a peer-reviewed journal, aims to cover all the latest outstanding developments in medicinal chemistry and rational drug design. The journal publishes original research, mini-review articles and guest edited thematic issues covering recent research and developments in the field. Articles are published rapidly by taking full advantage of Internet technology for both the submission and peer review of manuscripts. Medicinal Chemistry is an essential journal for all involved in drug design and discovery.
期刊最新文献
Synergistic Warriors: Design and Synthesis of Dual-Acting Schiff-Based Threaded 1,2,3-Triazole Hybrids for Potent Antineoplastic and Anti-Mycobacterial Activities. Design, Synthesis, Characterization, and Antitumor Activities of Benzimidazole-functionalized Organoruthenium Complexes Bearing Fluorine Group. In silico Identification and Computational Screening of Potential AFP Inhibitors Against Liver Cancer. Unlocking the Biological Potential of 2-Pyridones: Synthesis, Antioxidant and Antimicrobial Activity of N-Phenacylated 5/6-Chloro-2-pyridones. Discovery of the PARP1 Inhibitors from Natural Compounds Using Structure-Based Virtual Screening and Bioactivity Evaluation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1